Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Guidance on the use of the benchmark dose approach in risk assessment

Autor: EFSA Scientific Committee, More, Simon John, Bampidis, Vasileios, Benford, Diane, Bragard, Claude, Halldorsson, Thorhallur Ingi, Hernández-Jerez, Antonio F, Bennekou, Susanne Hougaard, Koutsoumanis, Kostas, Lambré, Claude, Machera, Kyriaki, Mennes, Wim, Mullins, Ewen, Nielsen, Søren Saxmose, Schrenk, Dieter, Turck, Dominique, Younes, Maged, Aerts, Marc, Edler, Lutz, Sand, Salomon, Wright, Matthew, Binaglia, Marco, Bottex, Bernard, Abrahantes, Jose Cortiñas, Schlatter, Josef

Publikováno v: EFSA Scientific Committee, More, S J, Bampidis, V, Benford, D, Bragard, C, Halldorsson, T I, Hernández-Jerez, A F, Bennekou, S H, Koutsoumanis, K, Lambré, C, Machera, K, Mennes, W, Mullins, E, Nielsen, S S, Schrenk, D, Turck, D, Younes, M, Aerts, M, Edler, L, Sand, S, Wright, M, Binaglia, M, Bottex, B, Abrahantes, J C & Schlatter, J 2022, ' Guidance on the use of the benchmark dose approach in risk assessment ', EFSA Journal, vol. 20, no. 10, e07584, pp. 1-67 . https://doi.org/10.2903/j.efsa.2022.7584

The Scientific Committee (SC) reconfirms that the benchmark dose (BMD) approach is a scientifically more advanced method compared to the no-observed-adverse-effect-level (NOAEL) approach for deriving a Reference Point (RP). The major change compared

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d570e368d40047fa9519c68dd7ee725
https://pubmed.ncbi.nlm.nih.gov/36304832

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Guidance on aneugenicity assessment

Autor: EFSA Scientific Committee (SC), More, Simon John, Bampidis, Vasileios, Bragard, Claude, Halldorsson, Thorhallur Ingi, Hernández-Jerez, Antonio F, Hougaard Bennekou, Susanne, Koutsoumanis, Kostas, Lambré, Claude, Machera, Kyriaki, Naegeli, Hanspeter, Nielsen, Søren Saxmose, Schlatter, Josef, Schrenk, Dieter, Turck, Dominique, Younes, Maged, Aquilina, Gabriele, Bignami, Margherita, Bolognesi, Claudia, Crebelli, Riccardo, Gürtler, Rainer, Marcon, Francesca, Nielsen, Elsa, Vleminckx, Christiane, Carfì, Maria, Martino, Carla, Maurici, Daniela, Parra Morte, Juan, Rossi, Annamaria, Benford, Diane

Publikováno v: EFSA Journal
EFSA Scientific Committee (SC) 2021, ' Guidance on aneugenicity assessment ', EFSA Journal, vol. 19, no. 8, e06770 . https://doi.org/10.2903/j.efsa.2021.6770
EFSA Journal, Vol 19, Iss 8, Pp n/a-n/a (2021)
EFSA Scientific Committee, More, S J, Bampidis, V, Bragard, C, Halldorsson, T I, Hernández-Jerez, A F, Hougaard Bennekou, S, Koutsoumanis, K, Lambré, C, Machera, K, Naegeli, H, Nielsen, S S, Schlatter, J, Schrenk, D, Turck, D, Younes, M, Aquilina, G, Bignami, M, Bolognesi, C, Crebelli, R, Gürtler, R, Marcon, F, Nielsen, E, Vleminckx, C, Carfì, M, Martino, C, Maurici, D, Parra Morte, J, Rossi, A & Benford, D 2021, ' Guidance on aneugenicity assessment ', EFSA Journal, vol. 19, no. 8, e06770, pp. 1-27 . https://doi.org/10.2903/j.efsa.2021.6770

The EFSA Scientific Committee was asked to provide guidance on the most appropriate in vivo tests to follow up on positive in vitro results for aneugenicity, and on the approach to risk assessment for substances that are aneugenic but not clastogenic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edd15ea78f24f0309a9e8a3d3bccd0f7